Publications by authors named "Zahra Ramji"
Article Synopsis
- * Lenvatinib achieved an objective response rate of 18.8% according to standard imaging criteria (RECIST v1.1) and 40.6% using a modified version (mRECIST), with responses noted early and lasting several months.
- * The study observed that tumor responses occurred in patients with more severe disease, highlighting lenvatinib's effectiveness even in challenging cases, although treatment-related adverse events were common
Introduction: Lenvatinib (dosing for patients who weigh ≥60 kg was 12 mg/day; for patients who weigh <60 kg, the dose was 8 mg/day) plus pembrolizumab 200 mg once every 3 weeks demonstrated antitumor activity and a manageable safety profile in patients with first-line unresectable hepatocellular carcinoma (uHCC) in the open-label phase 1b Study 116/KEYNOTE-524 (primary analysis data cutoff date: October 31, 2019; median follow-up: 10.6 months). This analysis (updated data cutoff date: March 31, 2021) reports efficacy results from 17 months of additional follow-up time.
View Article and Find Full Text PDFArticle Synopsis
- * In a study analyzing 476 patients from REFLECT, 212 developed CSTE-HTN, leading to numerically longer overall survival (OS) rates for those with hypertension compared to those without (16.3 vs. 11.6 months at 4 weeks).
- * The analysis indicates that while CSTE-HTN was associated with improved overall survival, it did not significantly alter progression-free survival (PFS); early detection and management of hypertension did not negatively impact treatment
Background: Increased understanding of how the immune system regulates tumor growth has innovated the use of immunotherapeutics to treat various cancers. The impact of such therapies, including programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, on the production of antidrug antibodies (ADAs) and their impact on outcomes, is poorly understood. This study aims to evaluate the clinical trial evidence on ADA incidence associated with PD-1, PD-L1, and CTLA-4 inhibitors in the treatment of cancer and to assess associations between treatment administered, ADA incidence, and treatment outcomes.
View Article and Find Full Text PDFArticle Synopsis
- Advanced practice providers (APPs) are crucial in detecting and managing adverse reactions (ARs) associated with lenvatinib, especially since these ARs can mimic cirrhosis linked to hepatocellular carcinoma (HCC).
- The post-hoc analysis of the REFLECT trial aimed to identify and discuss management strategies for key ARs related to lenvatinib treatment in patients with unresectable HCC.
- Key ARs typically presented within months of treatment initiation, and while they can often be managed by adjusting the dosage or withholding the drug, lenvatinib should be discontinued if a reaction is life-threatening.
Background: Lenvatinib is an approved first-line treatment for unresectable hepatocellular carcinoma (uHCC). We evaluated the safety and efficacy of lenvatinib sorafenib in patients with uHCC who deteriorated to Child-Pugh class B (CP-B) on treatment.
Methods: We retrospectively evaluated patients from REFLECT who deteriorated to CP-B those who remained Child-Pugh class A (CP-A) within 8 weeks after randomization.
Intra-articular bullet wounds have been found to cause both local and systemic consequences, in particular, when retained over many years. Only a few such cases have been described in published reports, each with different implications, depending on the joint involved and whether the patient experienced lead toxicity. We report the rare case of a 63-year-old male with lead arthropathy of the ankle secondary to a gunshot wound 49 years earlier.
View Article and Find Full Text PDF